In addition to overseeing the development of ChatGPT, Altman now serves as the chairman of Journey Colab, a pharmaceutical startup that is pursuing FDA approval for psychedelic medicines including mescaline, the use of which originated with Indigenous ceremonies involving the San Pedro cactus and peyote.14
Within the psychedelics industry, Journey Colab has been praised for its emphasis on Indigenous reciprocity, beginning with its decision to place 10 percent of its founding equity into an irrevocable “Reciprocity Trust” for the benefit of Indigenous communities and “other stake- holders in the psychedelic sector” (Journey Colab, 2022). In 2022, the startup also issued a “Patent Pledge” in which it committed to not enforcing its mescaline-related patents against any “Indigenous communities and practitioners who use mescaline for bona fide traditional ceremonial purposes” (Psychedelic Alpha, 2022). Following the analysis by Williams and Brant, such displays of reciprocity obscure a deeper, colonial imposition of power directed towards capital accumulation, enclosure, and extraction, which is inherently at odds with genuine reciprocity. Altman’s praise of Journey Colab’s reciprocity initiatives emphasizes capital accumulation as the driving goal: “Those [Indigenous] communities will share with Journey what they know of the history of these medicines, and Journey will share what Silicon Valley is good at, with how to use startups and capitalism to deliver something to people who can really benefit from it” (Al Idrus, 2020). For Altman, “reciprocity” is code for strategic research and development towards the further enrichment of Silicon Valley’s tech elites. In this context, Indigenous knowledge is framed as a source of extractable wealth to serve as grist for the TESCREAL mill.
^ The part about OpenAI and other tech elites funding research into synthetic mescaline for treatment of alcohol use disorder, is somehow extremely depressing. Perhaps because alcoholics are just a low-hanging fruit to be exploited in the service of larger profits, greater inequality (and consequently, the author implies, more alcoholism). Under different circumstances, the prospect of a mainstream psychedelic treatment for alcohol abuse should make anyone happy. But the social conditions that make alcohol abuse possible, and even likely, remain inviolable (misery and mental illness being an essential component of the business model). I don't see much hope that the masses will "organize" (as the article's author concludes) to resist such powerful forces as Big Tech with its newfangled (pharmacological) machines of loving grace.